SCHEMBL6296239

SCHEMBL6296239

CC(C)c1cc2nc(N)sc2cc1SC#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
SCN4A P35499 1/20 0.46
CYP3A4 P08684 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 2/20 0.44
USP2 O75604 1/20 0.39
USP8 P40818 1/20 0.39
USP5 P45974 1/20 0.39
USP4 Q13107 1/20 0.39
USP7 Q93009 1/20 0.39
MAPT P10636 1/20 0.39
DRD2 P14416 4/20 0.38
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
GAA P10253 2/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12237382 0.81 SMN1; SMN2 (0.60) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL10390811 0.80 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL614335 0.78 AXL (0.45) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL6296276 0.78 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL6296709 0.73 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL6303184 0.73 HTT (0.40) SMN1; SMN2USP2USP8USP5USP4
SCHEMBL6296382 0.72 USP2 (0.42) ALDH1A1USP2USP8USP5USP4
SCHEMBL6296223 0.70 ALDH1A1 (0.48) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL11712067 0.70 HSD17B10 (0.57) SMN1; SMN2RAB9ACYP3A4ALDH1A1TP53
SCHEMBL21091410 0.69 HSD17B10 (0.42) SMN1; SMN2CYP3A4ALDH1A1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD SMN1; SMN2 4359/4885RAB9A 3077/4885NPC1 787/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD SMN1; SMN2 4356/4885RAB9A 3024/4885NPC1 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.